1-5 of 5
Yan Lan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-088: Bintrafusp alfa enhances anti-tumor efficacy in combination with radiation therapy plus the ataxia telangiectasia mutated (ATM) inhibitor, M4076

Adam Lazorchak, Huakui Yu, Guozhong Qin, Jin Qi, Bo Marelli, Yan Lan
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8_Supplement): PO-088.
https://doi.org/10.1158/1557-3265.RADSCI21-PO-088
Published: 15 April 2021
View article titled, Abstract PO-088: Bintrafusp alfa enhances anti-tumor efficacy in combination with radiation therapy plus the ataxia telangiectasia mutated (ATM) inhibitor, M4076
Journal Articles

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models

Chunxiao Xu, Yanping Zhang, P. Alexander Rolfe, Vivian M. Hernández, Wilson Guzman, Giorgio Kradjian, Bo Marelli, Guozhong Qin, Jin Qi, Hong Wang, Huakui Yu, Robert Tighe, Kin-Ming Lo, Jessie M. English, Laszlo Radvanyi, Yan Lan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (19): 5869–5880.
https://doi.org/10.1158/1078-0432.CCR-17-0483
Published: 01 October 2017
View article titled, Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Open the PDF for Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models in another window
Includes: Supplementary data
Journal Articles

A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity

Stephen D. Gillies, Yan Lan, Thore Hettmann, Beatrice Brunkhorst, Yaping Sun, Stefan O. Mueller, Kin-Ming Lo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3673–3685.
https://doi.org/10.1158/1078-0432.CCR-10-2921
Published: 01 June 2011
View article titled, A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
Open the PDF for A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity in another window
Includes: Supplementary data
Journal Articles

Improved Circulating Half-Life and Efficacy of an Antibody-Interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis

Stephen D. Gillies, Kin-Ming Lo, Christa Burger, Yan Lan, Thomas Dahl, Wai-Keung Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (1): 210–216.
Published: 01 January 2002
View article titled, Improved Circulating Half-Life and Efficacy of an Antibody-Interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis
Open the PDF for Improved Circulating Half-Life and Efficacy of an Antibody-Interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis in another window
Journal Articles

Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents

Sylvia A. Holden, Yan Lan, Ana Maria Pardo, John S. Wesolowski, Stephen D. Gillies
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (9): 2862–2869.
Published: 01 September 2001
View article titled, Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents
Open the PDF for Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents in another window